Cargando…
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health
We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is considered a cause of variance and inconsistencies in trans...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232894/ https://www.ncbi.nlm.nih.gov/pubmed/34250423 http://dx.doi.org/10.1200/PO.20.00528 |
_version_ | 1783713733326929920 |
---|---|
author | Williams, P. Mickey Forbes, Thomas P. Lund, Steven Cole, Kenneth D. He, Hua-Jun Karlovich, Chris Paweletz, Cloud P. Stetson, Daniel Yee, Laura M. Connors, Dana E. Keating, Susan M. Destenaves, Benoit Cleveland, Megan H. Lau, Christie J. Barrett, J. Carl Kelloff, Gary J. McCormack, Robert T. |
author_facet | Williams, P. Mickey Forbes, Thomas P. Lund, Steven Cole, Kenneth D. He, Hua-Jun Karlovich, Chris Paweletz, Cloud P. Stetson, Daniel Yee, Laura M. Connors, Dana E. Keating, Susan M. Destenaves, Benoit Cleveland, Megan H. Lau, Christie J. Barrett, J. Carl Kelloff, Gary J. McCormack, Robert T. |
author_sort | Williams, P. Mickey |
collection | PubMed |
description | We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is considered a cause of variance and inconsistencies in translating ctDNA results into clinical actions. METHODS: In this phase I study, QCMs with 14 clinically relevant mutations representing single nucleotide variants, insertions or deletions (indels), translocations, and copy number variants were sourced from three commercial manufacturers with variant allele frequencies (VAFs) of 5%, 2.5%, 1%, 0.1%, and 0%. Four laboratories tested samples in quadruplicate using two allele-specific droplet digital polymerase chain reaction and three (amplicon and hybrid capture) next-generation sequencing (NGS) panels. RESULTS: The two droplet digital polymerase chain reaction assays reported VAF values very close to the manufacturers’ claimed concentrations for all QCMs. NGS assays reported most single nucleotide variants and indels, but not translocations, close to the expected VAF values. Notably, two NGS assays reported lower VAF than expected for all translocations in all QCM mixtures, possibly related to technical challenges detecting these variants. The ability to call ERBB2 copy number amplifications varied across assays. All three QCMs provided valuable insight into assay precision. Each assay across all variant types demonstrated dropouts at 0.1%, suggesting that the QCM can serve for testing of an assay’s limit of detection with confidence claims for specific variants. CONCLUSION: These results support the utility of the QCM in testing ctDNA assay analytical performance. However, unique designs and manufacturing methods for the QCM, and variations in a laboratory’s testing configuration, may require testing of multiple QCMs to find the best reagents for accurate result interpretation. |
format | Online Article Text |
id | pubmed-8232894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-82328942021-07-09 Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health Williams, P. Mickey Forbes, Thomas P. Lund, Steven Cole, Kenneth D. He, Hua-Jun Karlovich, Chris Paweletz, Cloud P. Stetson, Daniel Yee, Laura M. Connors, Dana E. Keating, Susan M. Destenaves, Benoit Cleveland, Megan H. Lau, Christie J. Barrett, J. Carl Kelloff, Gary J. McCormack, Robert T. JCO Precis Oncol Original Reports We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is considered a cause of variance and inconsistencies in translating ctDNA results into clinical actions. METHODS: In this phase I study, QCMs with 14 clinically relevant mutations representing single nucleotide variants, insertions or deletions (indels), translocations, and copy number variants were sourced from three commercial manufacturers with variant allele frequencies (VAFs) of 5%, 2.5%, 1%, 0.1%, and 0%. Four laboratories tested samples in quadruplicate using two allele-specific droplet digital polymerase chain reaction and three (amplicon and hybrid capture) next-generation sequencing (NGS) panels. RESULTS: The two droplet digital polymerase chain reaction assays reported VAF values very close to the manufacturers’ claimed concentrations for all QCMs. NGS assays reported most single nucleotide variants and indels, but not translocations, close to the expected VAF values. Notably, two NGS assays reported lower VAF than expected for all translocations in all QCM mixtures, possibly related to technical challenges detecting these variants. The ability to call ERBB2 copy number amplifications varied across assays. All three QCMs provided valuable insight into assay precision. Each assay across all variant types demonstrated dropouts at 0.1%, suggesting that the QCM can serve for testing of an assay’s limit of detection with confidence claims for specific variants. CONCLUSION: These results support the utility of the QCM in testing ctDNA assay analytical performance. However, unique designs and manufacturing methods for the QCM, and variations in a laboratory’s testing configuration, may require testing of multiple QCMs to find the best reagents for accurate result interpretation. Wolters Kluwer Health 2021-06-01 /pmc/articles/PMC8232894/ /pubmed/34250423 http://dx.doi.org/10.1200/PO.20.00528 Text en © 2021 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Reports Williams, P. Mickey Forbes, Thomas P. Lund, Steven Cole, Kenneth D. He, Hua-Jun Karlovich, Chris Paweletz, Cloud P. Stetson, Daniel Yee, Laura M. Connors, Dana E. Keating, Susan M. Destenaves, Benoit Cleveland, Megan H. Lau, Christie J. Barrett, J. Carl Kelloff, Gary J. McCormack, Robert T. Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health |
title | Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health |
title_full | Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health |
title_fullStr | Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health |
title_full_unstemmed | Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health |
title_short | Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health |
title_sort | validation of ctdna quality control materials through a precompetitive collaboration of the foundation for the national institutes of health |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232894/ https://www.ncbi.nlm.nih.gov/pubmed/34250423 http://dx.doi.org/10.1200/PO.20.00528 |
work_keys_str_mv | AT williamspmickey validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT forbesthomas validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT plundsteven validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT colekennethd validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT hehuajun validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT karlovichchris validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT paweletzcloudp validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT stetsondaniel validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT yeelauram validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT connorsdanae validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT keatingsusanm validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT destenavesbenoit validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT clevelandmeganh validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT lauchristiej validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT barrettjcarl validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT kelloffgaryj validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth AT mccormackrobertt validationofctdnaqualitycontrolmaterialsthroughaprecompetitivecollaborationofthefoundationforthenationalinstitutesofhealth |